Saxenda vs Zepbound

Saxenda (liraglutide 3 mg) and Zepbound (tirzepatide) are both FDA-approved for chronic weight management, but they represent different eras of obesity pharmacotherapy. Saxenda, approved in 2014, is a once-daily GLP-1 receptor agonist that was among the first incretin-based therapies validated for weight loss. Zepbound, approved in 2023, is a once-weekly dual GIP/GLP-1 receptor agonist that reflects the latest advances in incretin biology and has demonstrated substantially greater efficacy.

The efficacy difference between these medications represents a generational leap. In the SCALE trial, Saxenda produced mean weight loss of approximately 8% over 56 weeks. In the SURMOUNT-1 trial, Zepbound at the highest dose (15 mg) produced mean weight loss of approximately 22.5% over 72 weeks. While cross-trial comparisons carry inherent limitations, the nearly threefold difference in weight reduction is among the most dramatic improvements seen in obesity medicine. Zepbound's dual receptor mechanism -- activating both GIP and GLP-1 receptors -- is thought to contribute to enhanced appetite suppression and metabolic effects beyond what single-receptor GLP-1 agonists achieve.

Both medications share gastrointestinal side effects common to the incretin class, including nausea, vomiting, and diarrhea. Saxenda requires daily injections with a gradual dose escalation over several weeks, whereas Zepbound is injected once weekly. Saxenda has a substantially longer post-market safety record. Cost remains a significant factor for both medications, as insurance coverage for weight management drugs varies widely. Patients considering anti-obesity pharmacotherapy should discuss the available options with their healthcare provider, taking into account efficacy expectations, dosing preferences, medical history, and access.